Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 20.92 Billion KRW | 253.56% |
| 2022 | -7.54 Billion KRW | -586.06% |
| 2021 | 1.55 Billion KRW | -95.52% |
| 2020 | 34.68 Billion KRW | 95.51% |
| 2019 | 17.73 Billion KRW | 62.02% |
| 2018 | 10.94 Billion KRW | 3647.87% |
| 2017 | 292.15 Million KRW | -96.88% |
| 2016 | 9.35 Billion KRW | -28.86% |
| 2015 | 13.14 Billion KRW | 53.76% |
| 2014 | 8.55 Billion KRW | 522.92% |
| 2013 | 1.37 Billion KRW | -78.28% |
| 2012 | 6.32 Billion KRW | -80.74% |
| 2011 | 32.81 Billion KRW | -20.27% |
| 2010 | 41.16 Billion KRW | 6.81% |
| 2009 | 38.54 Billion KRW | 145.85% |
| 2008 | 15.67 Billion KRW | -11.89% |
| 2007 | 17.79 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -14.38 Billion KRW | -642.79% |
| 2024 Q1 | -1.93 Billion KRW | -41.86% |
| 2023 Q3 | 485.55 Million KRW | -43.39% |
| 2023 Q2 | 857.76 Million KRW | -95.35% |
| 2023 Q4 | -1.36 Billion KRW | -381.16% |
| 2023 FY | 11.59 Billion KRW | 253.56% |
| 2023 Q1 | 18.44 Billion KRW | 612.45% |
| 2022 Q3 | -223.75 Million KRW | -190.18% |
| 2022 Q2 | 248.1 Million KRW | 107.82% |
| 2022 Q1 | -3.17 Billion KRW | 64.59% |
| 2022 FY | -7.54 Billion KRW | -586.06% |
| 2022 Q4 | -3.6 Billion KRW | -1509.06% |
| 2021 Q4 | -8.95 Billion KRW | -865.85% |
| 2021 Q1 | 196.7 Million KRW | -94.33% |
| 2021 Q2 | 714.25 Million KRW | 263.11% |
| 2021 Q3 | -927.5 Million KRW | -229.86% |
| 2021 FY | 1.55 Billion KRW | -95.52% |
| 2020 Q4 | 3.46 Billion KRW | 15.26% |
| 2020 FY | 34.68 Billion KRW | 95.51% |
| 2020 Q1 | 8.54 Billion KRW | 221.87% |
| 2020 Q2 | 7.46 Billion KRW | -12.63% |
| 2020 Q3 | 3 Billion KRW | -59.71% |
| 2019 Q2 | 6.83 Billion KRW | 57.68% |
| 2019 Q1 | 4.33 Billion KRW | -4.49% |
| 2019 Q4 | -7 Billion KRW | -244.66% |
| 2019 Q3 | 4.84 Billion KRW | -29.1% |
| 2019 FY | 17.73 Billion KRW | 62.02% |
| 2018 FY | 10.94 Billion KRW | 3647.87% |
| 2018 Q4 | 4.53 Billion KRW | 84.65% |
| 2018 Q3 | 2.45 Billion KRW | 22.76% |
| 2018 Q2 | 2 Billion KRW | 2.63% |
| 2018 Q1 | 1.95 Billion KRW | 303.14% |
| 2017 Q2 | 197.68 Million KRW | -88.91% |
| 2017 FY | 292.15 Million KRW | -96.88% |
| 2017 Q1 | 1.78 Billion KRW | -71.32% |
| 2017 Q3 | 415.07 Million KRW | 109.97% |
| 2017 Q4 | -960.37 Million KRW | -331.37% |
| 2016 Q1 | 1.4 Billion KRW | 0.0% |
| 2016 Q3 | 1.13 Billion KRW | -14.4% |
| 2016 Q4 | 6.21 Billion KRW | 447.26% |
| 2016 Q2 | 1.32 Billion KRW | -5.27% |
| 2016 FY | 9.35 Billion KRW | -28.86% |
| 2015 FY | 13.14 Billion KRW | 53.76% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 2.38 Billion KRW | -48.59% |
| 2015 Q2 | 4.64 Billion KRW | 282.97% |
| 2015 Q1 | 1.21 Billion KRW | -16.89% |
| 2014 Q2 | 5 Billion KRW | 630.53% |
| 2014 Q1 | 684.45 Million KRW | 147.42% |
| 2014 FY | 8.55 Billion KRW | 522.92% |
| 2014 Q4 | 1.45 Billion KRW | 3.76% |
| 2014 Q3 | 1.4 Billion KRW | -71.86% |
| 2013 Q3 | 200.57 Million KRW | -81.75% |
| 2013 Q4 | -1.44 Billion KRW | -819.56% |
| 2013 FY | 1.37 Billion KRW | -78.28% |
| 2013 Q1 | 1.51 Billion KRW | 121.76% |
| 2013 Q2 | 1.09 Billion KRW | -27.52% |
| 2012 Q4 | -6.96 Billion KRW | -286.3% |
| 2012 FY | 6.32 Billion KRW | -80.74% |
| 2012 Q1 | 5.54 Billion KRW | 1429.17% |
| 2012 Q2 | 4 Billion KRW | -27.69% |
| 2012 Q3 | 3.74 Billion KRW | -6.65% |
| 2011 FY | 32.81 Billion KRW | -20.27% |
| 2011 Q4 | -416.91 Million KRW | -102.74% |
| 2011 Q3 | 15.2 Billion KRW | 184.38% |
| 2011 Q2 | 5.34 Billion KRW | -57.92% |
| 2011 Q1 | 12.7 Billion KRW | 196.42% |
| 2010 Q2 | 17.5 Billion KRW | 107.38% |
| 2010 FY | 41.16 Billion KRW | 6.81% |
| 2010 Q4 | 4.28 Billion KRW | -60.82% |
| 2010 Q3 | 10.93 Billion KRW | -37.52% |
| 2010 Q1 | 8.44 Billion KRW | -11.79% |
| 2009 Q1 | 6.27 Billion KRW | 53.89% |
| 2009 Q2 | 10.48 Billion KRW | 67.08% |
| 2009 Q3 | 10.81 Billion KRW | 3.16% |
| 2009 Q4 | 9.56 Billion KRW | -11.57% |
| 2009 FY | 38.54 Billion KRW | 145.85% |
| 2008 Q3 | 4.51 Billion KRW | 14.52% |
| 2008 Q2 | 3.94 Billion KRW | 30.99% |
| 2008 Q1 | 3.01 Billion KRW | -33.37% |
| 2008 Q4 | 4.07 Billion KRW | -9.69% |
| 2008 FY | 15.67 Billion KRW | -11.89% |
| 2007 Q1 | 3.84 Billion KRW | 0.0% |
| 2007 Q4 | 4.51 Billion KRW | -0.18% |
| 2007 Q3 | 4.52 Billion KRW | -7.58% |
| 2007 Q2 | 4.89 Billion KRW | 27.29% |
| 2007 FY | 17.79 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 364.53 Million KRW | -5638.836% |
| Dong-A Socio Holdings Co., Ltd. | 76.88 Billion KRW | 72.789% |
| Ildong Holdings Co., Ltd. | -79.56 Billion KRW | 126.294% |
| HANDOK Inc. | 12.57 Billion KRW | -66.313% |
| Kukje Pharma Co., Ltd. | -1.98 Billion KRW | 1151.719% |
| Yuhan Corporation | 74.56 Billion KRW | 71.943% |
| Dong-A ST Co., Ltd. | 11.17 Billion KRW | -87.147% |
| SAMSUNG PHARM. Co., LTD. | -18.04 Billion KRW | 215.949% |
| Hanmi Pharm. Co., Ltd. | 224.88 Billion KRW | 90.697% |
| Hanall Biopharma Co.,Ltd | 3.05 Billion KRW | -584.548% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -45.781% |
| Dong Sung Bio Pharm.Co.,Ltd. | 596.4 Million KRW | -3407.728% |
| MYUNGMOON Pharm co.,Ltd | 963.76 Million KRW | -2070.672% |
| Hana Pharm Co., Ltd. | 27.03 Billion KRW | 22.608% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -5638.836% |
| Ilsung Pharmaceuticals Co., Ltd. | -7.75 Billion KRW | 369.727% |
| REYON Pharmaceutical Co., Ltd. | 4.03 Billion KRW | -418.644% |
| Aprogen pharmaceuticals,Inc. | -69.95 Billion KRW | 129.907% |
| JW Holdings Corporation | 143.66 Billion KRW | 85.438% |
| Ildong Pharmaceutical Co., Ltd. | -53.41 Billion KRW | 139.163% |
| Chong Kun Dang Pharmaceutical Corp. | 246.59 Billion KRW | 91.517% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 79.143% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 144.142% |
| Hyundai Pharmaceutical Co., Ltd. | 6.92 Billion KRW | -202.012% |
| Samil Pharmaceutical Co.,Ltd | 6.47 Billion KRW | -223.29% |
| Jeil Pharmaceutical Co.,Ltd | 8.73 Billion KRW | -139.598% |
| Yuyu Pharma, Inc. | 364.53 Million KRW | -5638.836% |
| Kwang Dong Pharmaceutical Co., Ltd. | 48.76 Billion KRW | 57.102% |
| Daewoong pharmaceutical Co.,Ltd | 133.4 Billion KRW | 84.318% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 79.143% |
| Yuhan Corporation | 74.56 Billion KRW | 71.943% |
| Yungjin Pharm. Co., Ltd. | 3.11 Billion KRW | -571.079% |
| Suheung Co., Ltd. | 42.99 Billion KRW | 51.343% |
| JW Pharmaceutical Corporation | 100.3 Billion KRW | 79.143% |
| Samjin Pharmaceuticals Co., Ltd. | 20.48 Billion KRW | -2.128% |
| Korea United Pharm Inc. | 54.94 Billion KRW | 61.928% |
| CKD Bio Corp. | -20.15 Billion KRW | 203.809% |
| Daewon Pharmaceutical Co., Ltd. | 32.23 Billion KRW | 35.097% |
| Dongwha Pharm.Co.,Ltd | 25.3 Billion KRW | 17.318% |
| Whan In Pharm Co.,Ltd. | 32.52 Billion KRW | 35.68% |
| Shin Poong Pharm.Co.,Ltd. | -47.39 Billion KRW | 144.142% |
| Chong Kun Dang Holdings Corp. | 33.14 Billion KRW | 36.886% |
| Boryung Corporation | 68.26 Billion KRW | 69.355% |
| Bukwang Pharmaceutical Co., Ltd. | -37.49 Billion KRW | 155.792% |
| Ilyang Pharmaceutical Co.,Ltd | 14.35 Billion KRW | -45.781% |
| JW Lifescience Corporation | 32.09 Billion KRW | 34.811% |